MENU

AbbVie Inc’s Raised Bid Confirms My Shire PLC Sell Rating

shireLast Friday, I explained why I thought Shire (LSE: SHP) (NASDAQ: SHPG.US) shareholders should sell their shares, regardless of the possibility of an increased bid from US pharma firm AbbVie.

Earlier today, AbbVie did submit a raised bid — so was I wrong?

I still say sell

AbbVie’s raised bid is for £22.44 in cash and 0.8568 AbbVie shares for each Shire share. This equates to around £51 at today’s exchange rates.

The offer is an 11% increase on the previous £46 proposal, but interestingly, Shire’s share price has not budged following the news — indeed, as I write, Shire share price has started to fall, and is now down by 3% on this morning’s opening price.

What’s happening?

AbbVie claims to have “met with, or spoken to” Shire shareholders who represent the majority of Shire’s outstanding shares.

However, the fact that Shire’s share price has fallen following the new offer seems to suggest that the City doesn’t expect Shire’s management to take up the offer, increasing the chances that the bid will fall through by the 18 July  deadline.

Indeed, having looked at the details of the offer, I can see several problems with AbbVie’s new bid, which could explain the market’s lack of interest.

Not enough cash

Although this deal would have tax advantages for AbbVie, it might not do for Shire’s largest, long-term shareholders, who could face substantial capital gains tax bills.

Less than half the offer is in cash, so large UK shareholders would also be left with a big pile of AbbVie’s US-listed shares. In many cases, UK funds would be forced to sell these US shares straight after the deal went through, which would depress the price of AbbVie shares, reducing the real value of AbbVie’s offer.

Private shareholders in the UK would experience the same problems, and would face US share dealing and foreign exchange costs, too.

In my view, it seems fair to say that the true value of AbbVie’s revised offer, to most shareholders, is likely to be much less than £51.

Challenging valuation

A second problem is that Shire’s current share price places a seriously ambitious valuation on Shire’s business — around 23 times 2014 forecast earnings.

Shire shares trade at a premium of more than 20% to their pre-bid price, and have risen by 450% since 2009. For most shareholders, I think it’s time to take profits, de-risk, and sell — because Shire shares could plummet if the AbbVie bid fails.

A better opportunity?

If you've sold your Shire shares and are looking for new investment opportunities, then you might be interested in "The Motley Fool's Three Shares To Beat Property" -- an exclusive new report from the Motley Fool's market-beating analysts.

The report highlights three UK-listed stocks that provide attractive overseas exposure at low valuations -- one company highlighted currently offers a 4.4% prospective yield and a forecast P/E of just 10, despite expecting to report strong profits this year.

This FREE wealth report carries no obligation. To get your copy today, simply click here now.

> Roland does not own shares in any of the companies mentioned in this article. The Motley Fool has recommended shares in Shire.